Open Angle Glaucoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast  2024-2034

Open Angle Glaucoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Report Format: PDF+Excel | Report ID: SR112024A7383
Buy Now

Market Overview:

The 7 major open angle glaucoma markets reached a value of US$ 5.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 7.7 Billion by 2034, exhibiting a growth rate (CAGR) of 2.69% during 2024-2034.

Report Attribute
Key Statistics
Base Year 
2023
Forecast Years  2024-2034
Historical Years 
2018-2023
Market Size in 2023
US$ 5.8 Billion
Market Forecast in 2034
US$ 7.7 Billion
Market Growth Rate 2024-2034 2.69%


The open angle glaucoma market has been comprehensively analyzed in IMARC's new report titled "Open Angle Glaucoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Open angle glaucoma refers to a chronic, irreversible, and progressive multifactorial optic neuropathy in which the pressure inside the eye increases. It is mainly characterized by an open angle of the anterior chamber, changes to the optic nerve head, and progressive loss of peripheral vision, followed by the loss of the central visual field. There aren't any noticeable indications of this ailment in the early stage, but in the advanced stage, the condition manifests as reduced vision, eye pain or pressure, a swollen or bulging cornea, redness in the white of the eye, rainbow-colored halos around lights, headaches, nausea, vomiting, etc. The diagnosis of open angle glaucoma typically requires a combination of the patient's clinical features, medical history, and eye examination. Other common assessment tools utilized to confirm a diagnosis include pachymetry, slit-lamp exam, gonioscopy, visual field and visual acuity tests, etc. The healthcare provider may also perform optical coherence tomography to detect changes in the optic nerve that may cause the disease.

Open Angle Glaucoma Market

The rising cases of eye disorders, which increase resistance in the drainage canals and damage the optic nerve, are primarily driving the open angle glaucoma market. Besides this, the growing prevalence of several associated risk factors, including advanced age, family history, obesity, systemic diseases like diabetes and hypertension, etc., is also augmenting the market growth. Furthermore, the widespread adoption of effective medications, such as alpha-2 adrenergic agonists and carbonic anhydrase inhibitors, which decrease aqueous production and enhance uveoscleral outflow, thereby providing symptom relief, is creating a positive outlook for the market. Apart from this, the inflating utilization of minimally invasive glaucoma surgery (MIGS), owing to its numerous advantages, including improved outflow of fluid from the eye and faster recovery with potentially fewer side effects than traditional surgeries, is acting as another significant growth-inducing factor. Moreover, the emerging popularity of bimatoprost intracameral implant for treating the ailment, since it releases drugs directly to the targeted tissues and lowers intraocular pressure among patients, is expected to drive the open angle glaucoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the open angle glaucoma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for open angle glaucoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the open angle glaucoma market in any manner.

Recent Developments:

  • In May 2024, Sight Sciences, Inc. revealed the results of a large-scale, comparative real-world clinical outcomes study of patients treated with three leading minimally invasive glaucoma surgery (MIGS) technologies, which were published in the American Journal of Ophthalmology (AJO). The FDA had approved OMNI technology for canaloplasty and trabeculotomy to lower intraocular pressure (IOP) in adult patients with primary open-angle glaucoma.
  • In March 2024, Nicox SA stated that the results of the Mont Blanc pivotal Phase 3 trial comparing NCX 470 to latanoprost for decreasing IOP in patients with open-angle glaucoma have been published in the peer-reviewed journal AJO.
  • In December 2023, Glaukos announced that the FDA had approved a New Drug Application (NDA) for the iDose TR implant. The approval permits for iDose TR (travoprost intracameral implant) 75 mcg to be administered once per eye. The prostaglandin analog is indicated for the decrease of IOP in patients suffering from ocular hypertension or open-angle glaucoma.


Key Highlights:

  • Approximately 57.5 million people worldwide are affected with primary open-angle glaucoma.
  • Primary open-angle glaucoma (POAG) accounts for 12.3% of blindness worldwide.
  • POAG affects 1.86% of adults over the age of 40.
  • People in their seventies have a three to eight times higher prevalence of POAG.
  • Open-angle glaucoma affects about 2 million people in the United States.


Drugs:

ROCKLATAN (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is intended for lowering increased IOP in individuals with open-angle glaucoma or ocular hypertension. The recommended dose is a single drop in the affected eye(s) once daily in the evening.

NCX 470 is a novel nitric oxide-donating bimatoprost eye drop designed to decrease intraocular pressure in people with open-angle glaucoma or ocular hypertension.

QLS-101 is a new ATP-sensitive potassium (KATP) channel modulator given as a topical eyedrop. QLS-101 addresses distal outflow resistance and episcleral venous pressure (EVP), which are important components of IOP. To reduce IOP, QLS-101 widens outflow channels and episcleral arteries in the eye distal to the trabecular meshwork.


Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the open angle glaucoma market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the open angle glaucoma market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs


Competitive Landscape:

This report also provides a detailed analysis of the current open angle glaucoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance    
     

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     
Drugs Company Name
Rocklatan (Latanoprost/netarsudil) Alcon
Durysta (Bimatoprost sustained-release) AbbVie
Lumigan (Bimatoprost) AbbVie
Vyzulta (Latanoprostene bunod) Bausch & Lomb
Rescula (Unoprostone) R-Tech Ueno Ltd
NCX 470 NicOx
STN1012600 Santen Pharmaceutical
DE-130A Santen SAS
QLS 101 Qlaris bio
ONL1204 ONL Therapeutics


*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.


Key Questions Answered in this Report:

Market Insights

  • How has the open angle glaucoma market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the open angle glaucoma market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the open angle glaucoma market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?
     

Epidemiology Insights

  • What is the number of prevalent cases (​2018-2034​) of open angle glaucoma across the seven major markets?
  • What is the number of prevalent cases (​2018-2034​) of open angle glaucoma by age across the seven major markets?
  • What is the number of prevalent cases (​2018-2034​) of open angle glaucoma by gender across the seven major markets?
  • How many patients are diagnosed (​2018-2034​) with open angle glaucoma across the seven major markets?
  • What is the size of the open angle glaucoma patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of open angle glaucoma?
  • What will be the growth rate of patients across the seven major markets?
     

Open Angle Glaucoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for open angle glaucoma drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the open angle glaucoma market?
  • What are the key regulatory events related to the open angle glaucoma market?
  • What is the structure of clinical trial landscape by status related to the open angle glaucoma market?
  • What is the structure of clinical trial landscape by phase related to the open angle glaucoma market?
  • What is the structure of clinical trial landscape by route of administration related to the open angle glaucoma market?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Open Angle Glaucoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast  2024-2034
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More